Incidence and outcomes of paradoxical lymph node enlargement after anti-tuberculosis therapy in non-HIV patients - 28/09/13
Summary |
Objectives |
Limited data are available regarding the incidence and outcomes of lymphadenopathy after completing tuberculosis (TB) treatment.
Methods |
We prospectively evaluated the incidence and outcomes of post-treatment lymphadenopathy in 154 patients with newly diagnosed lymph node TB (group 1) and in 12 patients previously treated for TB (group 2). We assessed the rates of microbiological recurrence, clinical recurrence, and post-treatment paradoxical response (PR) (defined as no microbiological recurrence with spontaneous improvement).
Results |
Post-treatment lymphadenopathy occurred in 24 (15.6%) patients of group 1 and in 12 patients of group 2. Re-biopsy was performed in 23 of these 36 patients. AFB stain was positive in four (17.4%) cases, and TB-PCR was positive in 11 (47.8%), but all samples were sterile (no microbiological recurrence). Granuloma was present in 12 (52.2%) histological specimens. Thirty-three (91.7%) of the 36 patients with lymphadenopathy improved spontaneously (post-treatment PR) and 3 (8.3%) were improved with retreatment (clinical recurrence). The overall incidence of post-treatment PR in patients with lymph node TB (group 1) was 8.6 per 100 person-years (95% CI, 5.8–12.7).
Conclusions |
Lymphadenopathy after TB treatment was more likely to be associated with post-treatment PR rather than with microbiological recurrence, and it should be monitored until PR resolve.
Le texte complet de cet article est disponible en PDF.Keywords : Tuberculosis, Lymphadenopathy, Lymphadenitis, Paradoxical response
Plan
Vol 67 - N° 5
P. 408-415 - novembre 2013 Retour au numéro
Article précédent
- Comparative study of diagnostic accuracy of established PCR assays and in-house developed sdaA PCR method for detection of Mycobacterium tuberculosis in symptomatic patients with pulmonary tuberculosis
- Manoj Nimesh, Deepali Joon, Anil Kumar Pathak, Daman Saluja
- Time to positivity as prognostic tool in patients with Pseudomonas aeruginosa bloodstream infection
- Matthias Willmann, Ines Kuebart, Wichard Vogel, Ingo Flesch, Uwe Markert, Matthias Marschal, Klaus Schröppel, Ingo B. Autenrieth, Florian Hölzl, Silke Peter
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?